Zyrtec
Pfocus on Pfizer
Read the full article: http://blog.ockhamresearch.com/
For shareholders of Pfizer, Inc. (PFE) stock, it has been a pretty barren decade. No investor can look at Pfizer’s ten year chart and miss the fact that the stock has been a multi-year dog. However, from a valuation standpoint, these high-yielding shares are worthy of consideration for patient, income-oriented investors.
Vested Interest:
PFENo ticker information available.
- Login or register to post comments
- Email this page
Related Articles
- Pfocus on Pfizer
- GenVec, Inc.’s (GNVC) TNFerade™ Gets FDA Fast Track Designation for Pancreatic Cancer Treatment
- China Pharma Holdings Inc. (CPHI.OB) Posts Positive Q3 Results Across the Board
- BioScrip (BIOS) Quarterly Revenue and Net Income Soars
- Oxygen Biotherapeutics Inc. (OXBO.OB) to Submit Test Protocol to FDA for Multi-Center Study for Traumatic Brain Injury